Acta Pharmaceutica Sinica B
|
2026, 16(1): 93-121
• Reviews •
Structural biology of HIV-1 reverse transcriptase allosteric inhibitors for drug design
Full
Zhenzhen Zhou, Yanying Sun, Da Feng, Zhao Wang, Fabao Zhao, Shenghua Gao, Peng Zhan, Dongwei Kang, Xinyong Liu
Affiliations
doi: 10.1016/j.apsb.2025.11.007
Outline
HIV-1 reverse transcriptase (RT) is responsible for reverse transcription of viral single-stranded RNA to double-stranded DNA, which plays an important role in the replication cycle of HIV-1 and has been identified as a key target for anti-HIV-1 drug discovery. Among HIV-1 RT inhibitors, allosteric inhibitors acting on non-catalytic sites have the advantages of high efficiency and low cytotoxicity, which are the focus of the research on anti-HIV-1 inhibitors. Great progress has been achieved in the structural biology of HIV-1 RT, which significantly facilitated the development of RT allosteric inhibitors. Herein, we provided a detailed review of the co-crystal structures of small molecule allosteric inhibitors in complex with RT reported in the last decade. Moreover, the strategies to discover novel and efficient inhibitors based on co-crystal structures have also been discussed, expecting to provide a reference for the development of the next-generation anti-HIV-1 drugs.
HIV-1
/
Reverse transcriptase
/
Anti-HIV-1 drugs
/
NNRTIs
/
Structural biology
/
Allosteric inhibitors
/
Drug design
/
Drug resistance
Zhenzhen Zhou, Yanying Sun, Da Feng, Zhao Wang, Fabao Zhao, Shenghua Gao, Peng Zhan, Dongwei Kang, Xinyong Liu.
Structural biology of HIV-1 reverse transcriptase allosteric inhibitors for drug design[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(1)
: 93
-121
.
DOI: 10.1016/j.apsb.2025.11.007
Year 2026 volume 16 Issue 1
PDF
8
5
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2025.11.007
- Receive Date:2024-06-20
- Online Date:2026-09-17